Oxford Biomedica Signs 3-Year Commercial, Clinical Supply Agreement with Novartis
July 06 2017 - 4:02AM
Dow Jones News
LONDON--Oxford Biomedica PLC (OXB.LN) said Thursday it has
signed a three-year agreement with Novartis AG (NOVN.EB) for the
commercial and clinical supply of lentiviral vectors, a deal that
could bring $100 million to Oxford over the next three years.
The gene and cell therapy group said the agreement can be
extended to five years.
Lentiviral vectors are a type of retrovirus that can infect both
dividing and nondividing cells because their preintegration complex
can get through the intact membrane of the nucleus of the target
cell.
Chief Executive John Dawson said: "The new deal with Novartis
will strengthen the group's balance sheet immediately and will
support the group's continued growth over the next three
years."
Shares at 0725 GMT down 0.1 pence, or 1%, at 9.75 pence.
-Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
July 06, 2017 03:47 ET (07:47 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024